Telix Pharmaceuticals (TLX) furnishes JP Morgan 2026 conference presentation

Rhea-AI Filing Summary

Telix Pharmaceuticals Limited submitted a foreign issuer report to the U.S. securities regulator to furnish investors with a copy of a presentation given at the JP Morgan Healthcare Conference 2026. The company states that it filed an announcement with the Australian Securities Exchange on January 12, 2026 titled “Telix JP Morgan Healthcare Conference 2026 Presentation,” and has attached this as an exhibit for U.S. investors. This filing is primarily administrative, making the same information available in the U.S. market that was released in Australia.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

1

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On January 12, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian Securities Exchange titled “Telix JP Morgan Healthcare Conference 2026 Presentation,” which is attached to this Form 6-K as Exhibit 99.1.

99.1 Telix JP Morgan Healthcare Conference 2026 Presentation

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Telix Pharmaceuticals Limited
Date: January 12, 2026	By:	/s/ Genevieve Ryan
		Name: Genevieve Ryan
		Title: Company Secretary

FAQ

What does Telix Pharmaceuticals (TLX) disclose in this Form 6-K?

Telix Pharmaceuticals Limited discloses that it has filed an announcement with the Australian Securities Exchange titled “Telix JP Morgan Healthcare Conference 2026 Presentation” and is furnishing that presentation as an exhibit for U.S. investors.

Why did Telix (TLX) file this JP Morgan Healthcare Conference presentation with the SEC?

The company filed this report so that its JP Morgan Healthcare Conference 2026 presentation, already announced on the Australian Securities Exchange, is also available to U.S. investors through the U.S. securities regulator.

Does this Telix (TLX) Form 6-K include financial results or earnings data?

No specific financial results or earnings figures are described in this text. The report focuses on furnishing the conference presentation as an exhibit.

What is attached to Telix Pharmaceuticals’ January 12, 2026 Form 6-K?

The filing states that an announcement titled “Telix JP Morgan Healthcare Conference 2026 Presentation” is attached as Exhibit 99.1.

Who signed the Telix Pharmaceuticals (TLX) Form 6-K filed in January 2026?

The report is signed on behalf of Telix Pharmaceuticals Limited by Genevieve Ryan, who is identified as the Company Secretary, dated January 12, 2026.